This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-17. Anything still debated is marked as such rather than presented as settled.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Analytical method | LC-MS/MS | Preferred confirmatory technique |
| Appearance | White to off-white powder | Lyophilised form |
| Solubility | Freely soluble in water | Also described in saline |
| Storage temperature | Below -20 °C for powder | Short-term refrigeration for solutions |
| Regulatory status | Prohibited in sport | Listed under peptide hormones |
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
All patients were switched to or continued their treatments only with gemigliptin 50 mg qd during the extension period. A further decrease in HbA1c was observed in the continued treatment with gemigliptin 50 mg in this extension period, and the mean change from baseline at 52 weeks (–0.87%) was still clinically and statistically significant (full analysis set analysis, P<0.0001). In another blinded, active-controlled, phase III trial (study identifier: LG-DPCL011), eligible patients with HbA1c greater than 7.5% were randomized to receive gemigliptin 50 mg qd with metformin slow release (SR) qd (n=141), gemigliptin 50 mg qd (n=142), or metformin SR qd (n=150) for 24 weeks. After 24 weeks, the reduction from the baseline in HbA1c was –1.24% for gemigliptin monotherapy. In a meta-analysis involving data from 10 randomized controlled trials (1,792 patients), Dutta et al. demonstrated the good glycaemic efficacy, durability and safety of gemigliptin in managing type-2 diabetes Initial combination therapy with metformin In this randomized, blinded, active-controlled, phase III trial (study identifier: LG-DPCL011, INICOM study; ClinicalTrials.gov registration number: NCT01787396), eligible patients with an HbA1c greater than 7.5% were randomized to gemigliptin 50 mg qd+metformin SR qd (n=141), gemigliptin 50 mg qd (n=142), or metformin SR qd (n=150). From weeks 2 to 6, metformin SR was uptitrated incrementally from 500 to 2,000 mg/day maximum in the gemigliptin/metformin and metformin groups.
James Sherr, head of Russia and Eurasia Programme at Chatham House, wrote in The Telegraph: "The current crisis demonstrates that the Cold War has not been replaced by common values between East and West, but by the revival of hard Realpolitik. [...] Mikhail Saakashvili, Georgia's President, might have been profoundly unwise to employ massive force against the pro-Russian separatists in South Ossetia last Thursday, but his lapses of judgement are not the point. The commanders of Russian forces and their political masters in the Kremlin hoped he would behave exactly as he did. [...] Ukraine has no territorial conflicts, but it has a potential territorial dispute, Crimea." On 10 August 2008, Quentin Peel wrote in the Financial Times, "Saakashvili boosted military spending and refused to rule out the use of force. But he did not intend to use it. By all accounts he was unprepared for the latest confrontation: he was booked to be on a flight to Beijing." On 11 August 2008, The New York Times noted Putin's strong personal enmity towards Georgian president Saakashvili. On 11 August 2008, Robert Kagan wrote that the war was not a result of a "miscalculation" by Georgia, but "revanchist" Russia's attempt to respond to revolutions in Georgia and Ukraine.
== History == High-level vancomycin-resistant E. faecalis and E. faecium are clinical isolates first documented in Europe in 1986 and the United States in 1987. In the United States, vancomycin-resistant E. faecium was associated with 4% of healthcare-associated infections reported to the Centers for Disease Control and Prevention National Healthcare Safety Network from January 2006 to October 2007. VRE can be carried by healthy people who have come into contact with the bacteria, usually in a hospital (nosocomial infection), although it is thought that a significant percentage of intensively farmed chickens also carry VRE. Other regions have noted a similar distribution, but with increased incidence of VRE. For example, a 2006 study of nosocomial VRE revealed a rapid spread of resistance among enterococci along with an emerging shift in VRE distribution in the Middle East region, such as Iran. Treatment failures in enterococcal infections result from inadequate information regarding the glycopeptide resistance of endemic enterococci due to factors such as the presence of VanA and VanB. The study from Iran reported the first case of VRE isolates that carried the VanB gene in enterococcal strains from Iran. This study also noted the first documented isolation of nosocomial Enterococcus raffinosus and Enterococcus mundtii in the Middle East region.
The amino acids may then be linked together to form a protein. Proteins are broken down by first hydrolyzing them into their component amino acids. Further breakdown of these amino acids releases free ammonia (NH3), existing as the ammonium ion (NH4+) in blood, which is toxic to life forms. A suitable method for excreting it must therefore exist. Different tactics have evolved in different animals, depending on the animals' needs. Unicellular organisms release the ammonia into the environment. Likewise, bony fish can release ammonia into the water where it is quickly diluted. In general, mammals convert ammonia into urea, via the urea cycle. In order to determine whether two proteins are related, or in other words to decide whether they are homologous or not, scientists use sequence-comparison methods. Methods like sequence alignments and structural alignments are powerful tools that help scientists identify homologies between related molecules. Homology helps scientists understand the evolutionary relationships between proteins and extend understanding of their structure and thus their function.
Drugging a nation, the story of China and the opium curse; a personal investigation, during an extended tour, of the present conditions of the opium trade in China and its effects upon the nation. New York, Chicago [etc.] : F. H. Revell company. Morewood, Samuel (1838). A philosophical and statistical history of the inventions and customs of ancient and modern nations in the manufacture and use of inebriating liquors; with the present practice of distillation in all its varieties: together with an extensive illustration of the consumption and effects of opium, and other stimulants used in the East, as substitutes for wine and spirits. Dublin, W. Curry and W. Carson. William Muir (1875), The opium revenue: Sir William Muir's minute and other extracts from papers published by the Calcutta government; also extracts from parliamentary papers (1st ed.), London: The Anglo-Oriental Society for the Suppression of the Opium Trade, p. 30, Wikidata Q19095804 Musto, David F. The American Disease: Origins of Narcotic Control. New York: Oxford University Press, 1987. Nye, Gideon (1873). The morning of my life in China: comprising an outline of the history of foreign intercourse from the last year of the regime of honorable East India Company, 1833, to the imprisonment of the foreign community in 1839. Ouchterlony, John (1844). The Chinese war: an account of all the operations of the British forces from the commencement to the Treaty of Nanking. London: Saunders and Otley. Peters, Gretchen. Seeds of Terror: How Heroin is Bankrolling the Taliban and Al Qaeda, Thomas Dunne Books (2009).
Sources: en.wikipedia.org
DMG-PEG 2000 is a synthetic lipid formed by the PEGylation of myristoyl diglyceride. It is used to manufacture lipid nanoparticles that are used in mRNA vaccines, and in particular forms part of the drug delivery system for the Moderna COVID-19 vaccine.
== Left-handed structure == In principle, a left-handed version of the π-helix is possible by reversing the sign of the (φ, ψ) dihedral angles to (55°, 70°). This pseudo-"mirror-image" helix has roughly the same number of residues per turn (4.1) and helical pitch (1.5 Å [150 pm]). It is not a true mirror image, because the amino-acid residues still have a left-handed chirality. A long left-handed π-helix is unlikely to be observed in proteins because, among the naturally occurring amino acids, only glycine is likely to adopt positive φ dihedral angles such as 55°.
Several national and regional radio stations are relays for Le Havre: local information on France Bleu Haute Normandie, local relay from 12 noon to 4pm on Virgin radio Normandie 101.8 FM, local relay for Information from 6am to 9am and from 4pm to 8pm on NRJ Le Havre 92.5 FM. Associations like LHnouslanuit and Only-Hit have tried to develop alternative and cultural local radio by featuring local community associations (Papa's Production, Ben Salad Prod, Asso6Sons, Agend'Havre, Pied Nu, I Love LH).
The two substrates of this enzyme are (S)-dihydroorotic acid and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are orotic acid, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S)-dihydroorotate:NADP+ oxidoreductase. Other names in common use include orotate reductase, dihydroorotate dehydrogenase, dihydro-orotic dehydrogenase, L-5,6-dihydro-orotate:NAD+ oxidoreductase, and orotate reductase (NADPH). It has one cofactor, FAD.
=== Battery === Nuclear Magnetic Resonance (NMR) is a powerful analytical tool for investigating the local structure and ion dynamics in battery materials. NMR provides unique insights into the short-range atomic environments within complex electrochemical systems such as batteries. Electrochemical processes rely on redox reactions, in which 7Li or 23Na are often involved. Accordingly, their NMR spectroscopies are affected by the electronic structure of the material, which makes NMR an essential technique for probing the behavior of battery components during operation. Some of the applications of NMR in battery research include:
Sources: en.wikipedia.org
=== Excretion === The elimination of 2,6-DCBQ and its derivatives occurs predominantly through the renal system. Due to its high reactivity, levels of the unchanged parent compound are negligible. Instead, the compound is excreted in the form of water-soluble metabolites, specifically mercapturic acid derivatives. Biliary excretion is a secondary possibility, but urinary elimination remains the dominant pathway for the clearance of 2,6-DCBQ metabolites from the body.
=== Brand names === GABOB is sold primarily under the brand name Gamibetal. It has also been marketed under a variety of other brand names including Aminoxan, Bogil, Diastal, Gabimex, Gabomade, Gaboril, Gamalate, and Kolpo.
This was a controversial measure in Labour strongholds such as East London, Merseyside and North East England. He obtained a Treasury grant of £77 million to build the Docklands Light Railway, although transport links to Docklands remained inadequate. He opened Britain's first Enterprise Zone at Corby in Northamptonshire. Some criticism was made of his time in Liverpool that he spent a lot of money but generated little in the way of new employment ("I would not blame him for that: Liverpool had defeated better men than Michael Heseltine" commented Lady Thatcher acidly in her memoirs in 1993). Local Labour politicians tended to feel that he had accomplished little, although they acknowledged his good intentions. However a more positive assessment was offered by Michael Parkinson, Professor of Urban Affairs at John Moores University: although he had been sceptical in the 1980s, by 1997 he had come to favour the policies championed by Heseltine: assignment of ministers to regions, development of housing associations and cooperatives, and the channelling of government money through business-led agencies rather than through local government.
=== Plays === Habis, tragédie (1714) Cléarque, tyran d'Héraclée, tragédie (1733 - English translation: Cléarchus, Tyrant of Heraclea, a tragedy) Marsidie reine des Cimbres, tragédie (1735 - English translation: Marsidie, Queen of the Cimbri) Semiramis, tragédie (1737 - English translation: Semiramis, tragedy)
Sources: en.wikipedia.org
The most common approach is liquid chromatography with tandem mass spectrometry after extraction from blood or urine. Immunoassays exist but are generally treated as screening tools because of cross-reactivity.
Dry lyophilised powder is normally kept frozen and protected from moisture and light. Dissolved material is handled cold and used promptly to limit degradation.
It is not licensed as a medicine in major markets and is distributed as a research chemical. Sports organisations prohibit its use, and some countries restrict import and supply.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.